# The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

Study · id `cardio:ct-nct02258074` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02258074](<https://clinicaltrials.gov/study/NCT02258074>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02258074

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

## Technical summary

Registry record NCT02258074. Randomized; triple masking; primary purpose other. Start 2015-03 (actual); primary completion 2018-11 (actual). Results posted on 2021-07-30.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose other
- Phase: Phase 2
- Enrolled: 205 participants (enrolled count; ClinicalTrials.gov record NCT02258074, source copy `cardio:ctgov-nct02258074-2021-08-02`, retrieved 2026-10-26)
- Started: 2015-03 (actual) (ClinicalTrials.gov record NCT02258074, source copy `cardio:ctgov-nct02258074-2021-08-02`, retrieved 2026-10-26)
- Primary completion: 2018-11 (actual) (ClinicalTrials.gov record NCT02258074, source copy `cardio:ctgov-nct02258074-2021-08-02`, retrieved 2026-10-26)
- Completion: 2019-09 (actual) (ClinicalTrials.gov record NCT02258074, source copy `cardio:ctgov-nct02258074-2021-08-02`, retrieved 2026-10-26)
- Results first posted: 2021-07-30 (ClinicalTrials.gov record NCT02258074, source copy `cardio:ctgov-nct02258074-2021-08-02`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02258074, source copy `cardio:ctgov-nct02258074-2021-08-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02258074-2021-08-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
- Acronym: COMBINE
- Condition: Chronic Kidney Disease
- Intervention (Drug): Nicotinamide
- Intervention (Drug): Lanthanum Carbonate
- Intervention (Drug): Placebo (for Nicotinamide)
- Intervention (Drug): Placebo (for lanthanum carbonate)
- Lead sponsor: The Cleveland Clinic
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: The Cleveland Clinic (`cardio:org-the-cleveland-clinic`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial (`cardio:pubmed-31085679`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD (`cardio:pubmed-32345747`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 203d98a839131bc0fd65ccebb690322f2d9e81f083dd66332b0e041ce99647ce
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
